Despite Zoetis' underperformance relative to the broader market over the past year, Wall Street analysts maintain a bullish ...

Zoetis Inc. (NYSE:ZTS) is one of the best defensive stocks to invest in according to analysts. On July 10, Bank of America ...

Zoetis (NYSE:ZTS) added ~7% in the premarket on Tuesday after the animal health company exceeded Street forecasts with its Q2 ...

Zoetis stock reversed Tuesday, sinking into the red, despite beating second-quarter expectations as Librela sales continued ...

Zoetis raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and ...

Meanwhile, the company has an impeccable dividend program. The company has increased its payouts by 502% over the past decade ...

Shares of Zoetis Inc. ZTS slipped 1.46% to $148.81 Wednesday, on what proved to be an all-around grim trading session for the ...

Shares of Zoetis Inc. ZTS rallied 1.09% to $147.38 Friday, on what proved to be an all-around dismal trading session for the ...

(ZTS) on Tuesday reported second-quarter net income of $718 million. The Parsippany, New Jersey-based company said it had profit of $1.

Breed Explorer offers veterinarian-approved, science-backed insights to help current and prospective pet owners make informed ...

Zoetis enjoys enviable financial flexibility, even as leverage ticked up in 2015 to finance the purchase of Pharmaq and Abbott's animal health business. With long-term debt at roughly $5.2 billion ...

Zoetis’s companion animal portfolio was the main driver of revenue growth for the quarter, as sales of companion animal products grew 25% in the United States and 10% internationally.